Physician profile
Edward Singh
NPI 1629076260
$6,042.07
in general payments reported to CMS, 2019-2025
12 companies · $520 in 2025
The $520 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $96.57 · 2021: $340 · 2022: $260 · 2023: $567 · 2024: $3,572 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $1,750 · Travel and Lodging: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $1,749.58 |
| Travel and Lodging | $308.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,440.03 | 2019-2024 | Tremfya, Xarelto |
| Abbvie INC. | $1,120.24 | 2021-2025 | Mavyret, Skyrizi, Rinvoq |
| Janssen Scientific Affairs, LLC | $290.68 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $257.44 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $230.53 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $146.57 | 2019-2020 | |
| Madrigal Pharmaceuticals | $143.90 | 2025 | Rezdiffra |
| Lilly USA, LLC | $125.00 | 2024 | Omvoh |
| Allergan, INC. | $92.78 | 2019 | |
| Pfizer Pharmaceuticals LLC | $78.24 | 2019 | |
| Pbg Puerto Rico LLC | $76.83 | 2021 | |
| Apollo Endosurgery US INC | $39.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.